[CLSTR]
< Back to situation

[REVISION HISTORY]

Heidi Overton FDA commissioner nomination

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-26 21:17 UTC → 2026-09-01 17:53 UTC · added removed

President Donald Trump has nominated Dr. Heidi Overton, a physician and White House domestic policy aide, to serve as the commissioner of the Food and Drug Administration (FDA). Overton would succeed Marty Makary, who resigned in May. The nomination has drawn varied reactions. Senator Bill Cassidy, chairman of the Senate health committee, expressed concerns regarding her suitability, specifically citing her support for an executive order to alter childhood vaccination schedules. Critics have also highlighted her previous work at the America First Policy Institute and her stances on reproductive rights. Conversely, pro-life organizations have expressed support. John Mize of Americans United for Life (AUL) praised her medical background and expressed optimism that she could bring objectivity to the scrutiny of mifepristone. AUL anticipates she will be a ‘pro-life FDA commissioner’ who may expose potential damages caused by the abortion drug. This scrutiny follows a recent incident in North Carolina where an individual was accused of using the medication well beyond its approved 10-week limit. Additionally, Lila Rose of Live Action President Trump has called for since urged the commissioner Senate to prioritize Overton’s confirmation before the 2026 midterm elections, noting that HHS Secretary Robert F. Kennedy Jr. also desires a swift process. The confirmation may face political hurdles, as Senate hearings could force Republicans to address abortion rights. The Senate is not scheduled to return to Washington until September 14. The FDA is a massive regulatory agency with a budget of approximately $7 billion. Following cuts implemented by the availability Department of abortion pills. Overton was selected for Government Efficiency (DOGE), the role over other candidates, including Stephen Ferrara and Jeff Vacirca. agency’s workforce has been reduced from 18,200 to roughly 16,000 employees. If confirmed, she Overton is tasked with advancing the ‘Make America Healthy Again’ movement, movement and reforming clinical trials, and accelerating medical innovation. Her administration will work alongside HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz to address drug prices and oversee agency functions such as the Center for Tobacco Products. trials.

Versions

  1. 2026-09-01 17:53 UTC Heidi Overton FDA commissioner nomination
  2. 2026-08-26 21:17 UTC Heidi Overton FDA commissioner nomination
  3. 2026-08-26 00:37 UTC Heidi Overton FDA commissioner nomination
  4. 2026-08-22 03:38 UTC Heidi Overton FDA commissioner nomination

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.